Genetic Influence on Statin Pharmacodynamics
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01569854 |
Recruitment Status
:
Withdrawn
(Insufficient recruitment)
First Posted
: April 3, 2012
Last Update Posted
: September 27, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Hyperlipidemia Hypercholesterolemia Dyslipidemia |
Study Type : | Observational |
Actual Enrollment : | 0 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | An Observational Study Investigating Genetic Influences on Clinical Outcomes and Change in Carotid Intimal Thickness in Adults Taking Atorvastatin, Simvastatin, or Lovastatin |
Study Start Date : | March 2012 |
Estimated Primary Completion Date : | March 2016 |
Estimated Study Completion Date : | March 2022 |
Group/Cohort |
---|
statin |
- carotid intimal media thickness (CIMT) [ Time Frame: 2 years ]CIMT measurements will be performed at baseline (within 3 months of starting statin) and at 6, 12, 18, and 24 months. Change in CIMT is considered a surogate measure of atherosclerotic progression.
Biospecimen Retention: Samples With DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- recently (within past 3 months) started taking atorvastatin, lovastatin, or simvastatin
Exclusion Criteria:
- concomitant uses of medications, supplements, or OTCs known to interfere with statin metabolism

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01569854
United States, Ohio | |
Ohio State University Medical Center | |
Columbus, Ohio, United States, 43210 |
Principal Investigator: | Joseph P Kitzmiller, MD PhD | Ohio State University |
Responsible Party: | Joseph Kitzmiller, Assistant Professor, Ohio State University |
ClinicalTrials.gov Identifier: | NCT01569854 History of Changes |
Other Study ID Numbers: |
OSU 2011H0261 K23GM100372 ( U.S. NIH Grant/Contract ) |
First Posted: | April 3, 2012 Key Record Dates |
Last Update Posted: | September 27, 2016 |
Last Verified: | September 2016 |
Additional relevant MeSH terms:
Hypercholesterolemia Dyslipidemias Hyperlipidemias |
Hyperlipoproteinemias Lipid Metabolism Disorders Metabolic Diseases |